Modified AAV Capsids for Brain Microvasculature Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV variants lack the ability to efficiently target brain microvasculature, limiting their effectiveness in treating diseases affecting the blood-brain barrier and central nervous system.
Innovation Solution
Development of modified AAV capsid proteins with targeting peptides that specifically target brain endothelial cells, inserted at specific residues and flanked by linker sequences, enhancing transduction efficiency to the brain microvasculature.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional AAV capsids are used, then the viral vector can be produced with standard efficiency, but it cannot efficiently target brain microvasculature
Solution Approach 1:
The patent applies local quality by introducing a specific targeting peptide sequence (3-10 amino acids) at a defined location (after residue 590) in the AAV1 capsid protein. This localized modification creates a specific binding region that enables selective interaction with brain microvasculature components, thereby improving targeting efficiency without requiring complete redesign of the entire capsid structure.
Solution Approach 2:
The patent employs parameter changes by modifying the amino acid sequence at specific positions in the capsid protein. The targeting peptide is inserted after residue 590 of the AAV1 capsid protein, and linker sequences of specific lengths (2-3 amino acids) are used to flank the targeting peptide. These parameter modifications optimize the capsid's interaction with brain microvasculature while maintaining overall capsid functionality.
2Reliability
If targeting peptide is inserted into AAV capsid protein, then specificity to brain endothelial cells is improved, but capsid protein structure complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the capsid protein into functional regions: the original capsid protein sequence (residues 1-589), the inserted targeting peptide (3-10 amino acids), and linker sequences (2-3 amino acids) on each side. This segmented approach allows the targeting peptide to be introduced as a discrete functional element without disrupting the overall capsid protein folding and structure.
Solution Approach 2:
The patent uses linker sequences as intermediary elements between the capsid protein and the targeting peptide. These linker sequences (2-3 amino acids long, such as SSA on the N-terminal side and AS on the C-terminal side) serve as flexible connectors that maintain proper protein structure while enabling the targeting peptide to functionally interact with brain endothelial cells.
3Adaptability or versatility
If AAV vector is designed for general delivery, then broad tissue tropism is achieved, but inability to specifically target brain microvasculature limits therapeutic effectiveness
Solution Approach 1:
The patent applies local quality by introducing a specific targeting peptide sequence (3-10 amino acids) at a defined location (after residue 590) in the AAV1 capsid protein. This localized modification creates a specific binding region that enables selective interaction with brain microvasculature components, thereby improving targeting efficiency without requiring complete redesign of the entire capsid structure.
Solution Approach 2:
The patent achieves multi-functionality by maintaining the original AAV1 capsid protein's general delivery capabilities while adding a specific targeting peptide function. The capsid protein continues to provide broad tissue tropism and cellular entry functions, while the inserted targeting peptide specifically directs the vector to brain endothelial cells, enabling the same vector to perform multiple functions.
Data Source
AI summary
Provided herein are targeting peptides and vectors containing a sequence that encodes the targeting peptides that deliver agents to the brain microvasculature.